# Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

> **NCT02226120** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1980 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT02226120
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-16
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 1980 (ACTUAL)
- **Last updated:** 2019-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226120, "Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02226120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*